Donepezil for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled Trial

Bruera, Éduardo; Osta, Badi El; Valero, Vicente; Driver, Larry C.; Pei, Be Lian; Shen, Lan; Poulter, V.; Palmer, J. Lynn

doi:10.1200/jco.2007.10.9231

Cited by 99 publications

(56 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, as some studies showed considerable response to placebo, using appropriate placebo treatment should be considered in the future studies. 29,30 Another limitation is the two week treatment period without follow-up. While many studies use 1-or 2-week treatment period in the clinical trial setting, 30,31 it would be appropriate in the future studies to administer for longer periods of time with longterm follow-up research as fatigue is a rather chronic symptom and in most cases, affecting the patients longer than several weeks.…”

Section: Discussionmentioning

confidence: 99%

“…29,30 Another limitation is the two week treatment period without follow-up. While many studies use 1-or 2-week treatment period in the clinical trial setting, 30,31 it would be appropriate in the future studies to administer for longer periods of time with longterm follow-up research as fatigue is a rather chronic symptom and in most cases, affecting the patients longer than several weeks. A recent study by Kobayashi et al 32 also adopted a longer administration protocol with Bojungikkitang, which is considered to work in a slower manner.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bojungikki-Tang for Cancer-Related Fatigue: A Pilot Randomized Clinical Trial

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Bojungikki-Tang for Cancer-Related Fatigue: A Pilot Randomized Clinical Trial

et al. 2010

View full text Add to dashboard Cite

show abstract

“…We chose the FACIT-F score as the primary outcome measure because it has been widely used in CRF treatment trials by our team and others. [40][41][42][43] Test-retest reliability coefficients for the FACIT-F have ranged from .84 to .90. 44 This scale has been shown to have strong internal consistency (α = .93-.95) and has a sensitivity of 0.92 and specificity of 0.69.…”

Section: Outcome Measuresmentioning

confidence: 99%

High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue

et al. 2015

Self Cite

View full text Add to dashboard Cite

Introduction and Objective. Cancer-related fatigue (CRF) is the most common and severe symptom in patients with cancer. The number and efficacy of available treatments for CRF are limited. The objective of this preliminary study was to assess the safety of high-dose Panax ginseng (PG) for CRF. Methods. In this prospective, open-label study, 30 patients with CRF (≥4/10) received high-dose PG at 800 mg orally daily for 29 days. Frequency and type of side effects were determined by the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0. Scores on the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) scale, Edmonton Symptom Assessment System (ESAS), and Hospital Anxiety and Depression Scale (HADS) were assessed at baseline, day 15, and day 29. Global Symptom Evaluation (GSE) was assessed at day 29. Results. Of the 30 patients enrolled, 24 (80%) were evaluable. The median age was 58 years; 50% were females, and 84% were white. No severe (≥grade 3) adverse events related to the study drug were reported. Of the 24 evaluable patients, 21 (87%) had an improved (by ≥3 points) FACIT-F score by day 15. The mean ESAS score (standard deviation) for well-being improved from 4.67 (2.04) to 3.50 (2.34) ( P = .01374), and mean score for appetite improved from 4.29 (2.79) to 2.96 (2.46) ( P = .0097). GSE score of PG for fatigue was ≥3 in 15/24 patients (63%) with median improvement of 5. Conclusion. PG is safe and improves CRF fatigue as well as overall quality of life, appetite, and sleep at night. Randomized controlled trials of PG for CRF are justified.

show abstract

“…The time frame evaluated varied from hours [28,53] to months [52,64]. Some symptom toxicity instruments, like Morrow Assessment of Nausea and Emesis (MANE) [67,72,73], Worthing Chemotherapy Questionnaire (WCQ) [52], and single ESAS items considered specific treatment-related change ( Table 2).…”

Section: (B) Factor Analysismentioning

confidence: 99%

The psychometric properties of cancer multisymptom assessment instruments: a clinical review

Aktaş

Walsh

Kirkova

2015

Support Care Cancer

View full text Add to dashboard Cite

The MDASI appeared to be the best overall from a psychometric perspective. This was followed by the ESAS, ESAS-Spanish, POMS, SDS, and some MDASI translations. VRS-based instruments were most common. There was a wide range of psychometric rigor in validation. Consequently, meta-analysis was not possible. Most cancer multisymptom assessment instruments need further extensive validation to establish the excellent reliability and validity required for clinical utility and meaningful research.

show abstract

Donepezil for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled Trial

Abstract: Donepezil was not significantly superior to placebo in the treatment of cancer-related fatigue.

Cited by 99 publications

References 27 publications

Bojungikki-Tang for Cancer-Related Fatigue: A Pilot Randomized Clinical Trial

Bojungikki-Tang for Cancer-Related Fatigue: A Pilot Randomized Clinical Trial

High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue

The psychometric properties of cancer multisymptom assessment instruments: a clinical review

Contact Info

Product

Resources

About